Blockchain Registration Transaction Record

NeuroOne's OneRF System Shows Promise in Treating Drug-Resistant Epilepsy

NeuroOne's FDA-cleared OneRF Ablation System shows safe, effective treatment for drug-resistant epilepsy in peer-reviewed study, reducing seizures with real-time monitoring.

This development matters because drug-resistant epilepsy affects millions worldwide, often requiring multiple invasive procedures with significant risks and recovery times. NeuroOne's OneRF system addresses this by enabling both diagnosis and treatment in a single minimally invasive procedure, potentially reducing hospital stays, surgical complications, and healthcare costs. For patients, this means fewer interventions, quicker recovery, and improved seizure control, enhancing quality of life. In the broader medical landscape, it represents a shift toward integrated therapeutic technologies that streamline care for complex neurological disorders, setting a precedent for future innovations in precision medicine.